Troglitazone is an estrogen-related receptor alpha and gamma inverse agonist.

As a ligand for peroxisome proliferators-activated receptor gamma (PPAR gamma), troglitazone inhibits cell growth by mechanisms besides activating PPAR gamma. In this study, we found that troglitazone interfered with the interactions between estrogen-related receptor alpha and gamma (ERR alpha and ERR gamma) and their coactivator PPAR gamma coactivator-1 alpha (PGC-1 alpha) functioning as an inverse agonist. Additionally, troglitazone suppressed the expressions of PGC-1 alpha and its related member PGC-1 beta which are key regulators of mitochondrial function. Consequently, troglitazone reduced mitochondrial mass and suppressed the expressions of superoxide dismutases to elevate reactive oxygen species (ROS) production. The increase in ROS in turn induced the expression of cell cycle inhibitor p21(WAF1). We therefore propose that ERR alpha and ERR gamma are alternative targets of troglitazone important for mediating its growth suppressive effect.

[1]  J. G. Alvarez,et al.  Activators of the nuclear receptor PPARγ enhance colon polyp formation , 1998, Nature Medicine.

[2]  E. Siegel,et al.  Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Halperin,et al.  Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. , 2001, Cancer research.

[4]  Y. Kamei,et al.  PPARγ coactivator 1β/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[5]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[6]  B. Spiegelman,et al.  Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. , 2006, Endocrine reviews.

[7]  P. Puigserver,et al.  A Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis , 1998, Cell.

[8]  Jong-Suk Kim,et al.  Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells. , 2008, Biochemical and biophysical research communications.

[9]  P. Fisher,et al.  Up-regulation of p21 Gene Expression by Peroxisome Proliferator-Activated Receptor γ in Human Lung Carcinoma Cells , 2004, Clinical Cancer Research.

[10]  J. Auwerx,et al.  Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice , 1998, Nature Medicine.

[11]  J. Copland,et al.  Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor gamma ligands in uterine leiomyoma. , 2003, Cancer research.

[12]  V. Giguère.  Transcriptional control of energy homeostasis by the estrogen-related receptors. , 2008, Endocrine reviews.

[13]  J. Lehmann,et al.  4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor γ , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Y. Chapleur,et al.  Disruption of ERα signalling pathway by PPARγ agonists: evidences of PPARγ-independent events in two hormone-dependent breast cancer cell lines , 2008, Breast Cancer Research and Treatment.

[15]  M. Korbonits,et al.  PPAR‐γ expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti‐proliferative effect of the glitazones is independent of the PPAR‐γ receptor , 2006, Clinical endocrinology.

[16]  G. Labesse,et al.  The nuclear receptor coactivator PGC-1alpha exhibits modes of interaction with the estrogen receptor distinct from those of SRC-1. , 2005, Journal of molecular biology.

[17]  H. Koeffler.  Peroxisome proliferator-activated receptor γ and cancers , 2003 .

[18]  E. Fleck,et al.  Regulation of the Growth Arrest and DNA Damage-Inducible Gene 45 (GADD45) by Peroxisome Proliferator-Activated Receptor &ggr; in Vascular Smooth Muscle Cells , 2003, Circulation research.

[19]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[20]  Y. Wang,et al.  Oestrogen‐related receptor alpha inverse agonist XCT‐790 arrests A549 lung cancer cell population growth by inducing mitochondrial reactive oxygen species production , 2010, Cell proliferation.

[21]  J. Jordán,et al.  Glitazones Differentially Regulate Primary Astrocyte and Glioma Cell Survival , 2004, Journal of Biological Chemistry.

[22]  D. McDonnell,et al.  Estrogen-related receptor alpha as a therapeutic target in cancer. , 2006, Endocrine-related cancer.

[23]  S. Kong,et al.  Estrogen-related receptor alpha (ERRalpha) inverse agonist XCT-790 induces cell death in chemotherapeutic resistant cancer cells. , 2009, Chemico-biological interactions.

[24]  Jiandie D. Lin,et al.  Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators , 2006, Cell.

[25]  Lihua Chen,et al.  Estrogen-Related Receptor α Inverse Agonist Enhances Basal Glucose Uptake in Myotubes through Reactive Oxygen Species , 2009 .

[26]  F. Fang,et al.  Kaempferol is an estrogen‐related receptor α and γ inverse agonist , 2009, FEBS letters.

[27]  J. Vanacker,et al.  Estrogen receptor-related receptors: orphan receptors desperately seeking a ligand. , 2003, Journal of molecular endocrinology.

[28]  Yaohui Nie,et al.  Suppressing the activity of ERRα in 3T3-L1 adipocytes reduces mitochondrial biogenesis but enhances glycolysis and basal glucose uptake , 2008, Journal of cellular and molecular medicine.

[29]  David M. Thomas,et al.  PPARγ-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma , 2006, BMC Cancer.

[30]  F. Ondrey,et al.  Peroxisome Proliferator-Activated Receptor γ Pathway Targeting in Carcinogenesis: Implications for Chemoprevention , 2009, Clinical Cancer Research.

[31]  L. Yee,et al.  Clinical Use of PPARγ Ligands in Cancer , 2008, PPAR research.

[32]  Chi-Wai Wong,et al.  Structural activity relationship of flavonoids with estrogen‐related receptor gamma , 2010, FEBS letters.

[33]  W. Stevens,et al.  Identification of a selective inverse agonist for the orphan nuclear receptor estrogen-related receptor alpha. , 2004, Journal of medicinal chemistry.

[34]  B. Spiegelman,et al.  The transcriptional coactivator PGC-1beta drives the formation of oxidative type IIX fibers in skeletal muscle. , 2007, Cell metabolism.

[35]  B. Staels,et al.  Therapeutic roles of peroxisome proliferator-activated receptor agonists. , 2005, Diabetes.